Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

645 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Recommendations for the Management of Drug-Drug Interactions Between the COVID-19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications.
Marzolini C, Kuritzkes DR, Marra F, Boyle A, Gibbons S, Flexner C, Pozniak A, Boffito M, Waters L, Burger D, Back DJ, Khoo S. Marzolini C, et al. Among authors: marra f. Clin Pharmacol Ther. 2022 Dec;112(6):1191-1200. doi: 10.1002/cpt.2646. Epub 2022 Jun 7. Clin Pharmacol Ther. 2022. PMID: 35567754 Free PMC article. Review.
Clinical impact of pharmacokinetic interactions between the HCV protease inhibitor simeprevir and frequently used concomitant medications.
Marra F, Höner Zu Siederdissen C, Khoo S, Back D, Schlag M, Ouwerkerk-Mahadevan S, Bicer C, Lonjon-Domanec I, Jessner W, Beumont-Mauviel M, Kalmeijer R, Cornberg M. Marra F, et al. Br J Clin Pharmacol. 2018 May;84(5):961-971. doi: 10.1111/bcp.13519. Epub 2018 Feb 21. Br J Clin Pharmacol. 2018. PMID: 29345798 Free PMC article.
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.
Ferenci P, Bourgeois S, Buggisch P, Norris S, Curescu M, Larrey D, Marra F, Kleine H, Dorr P, Charafeddine M, Crown E, Bondin M, Back D, Flisiak R. Ferenci P, et al. Among authors: marra f. J Viral Hepat. 2019 Jun;26(6):685-696. doi: 10.1111/jvh.13080. Epub 2019 Mar 5. J Viral Hepat. 2019. PMID: 30739368 Free PMC article.
Frequency of Potential Drug-Drug Interactions in the Changing Field of HCV Therapy.
Schulte B, Wübbolding M, Marra F, Port K, Manns MP, Back D, Cornberg M, Stichtenoth DO, Höner Zu Siederdissen C, Maasoumy B. Schulte B, et al. Among authors: marra f. Open Forum Infect Dis. 2020 Feb 3;7(2):ofaa040. doi: 10.1093/ofid/ofaa040. eCollection 2020 Feb. Open Forum Infect Dis. 2020. PMID: 32104719 Free PMC article.
Fluvoxamine for the treatment of COVID-19.
Marzolini C, Marra F, Boyle A, Khoo S, Back DJ. Marzolini C, et al. Among authors: marra f. Lancet Glob Health. 2022 Mar;10(3):e331. doi: 10.1016/S2214-109X(21)00592-1. Lancet Glob Health. 2022. PMID: 35180411 Free PMC article. No abstract available.
645 results